Intravenous zoledronate (Reclast) administered once every 5 years reduced the incidence of morphometric vertebral fractures in early postmenopausal women, a randomized trial showed. Over 10 years ...
Hosted on MSN1mon
Zoledronate Prevents Morphometric Vertebral Fractures Over 10 YearsWEDNESDAY, Jan. 15, 2025 (HealthDay News) -- For early postmenopausal women, zoledronate administered at baseline and five years is effective for preventing morphometric vertebral fracture ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback